Trade Names:Xalatan- Ophthalmic solution 0.005%
Prostaglandin F 2α analog that reduces IOP by increasing the output of aqueous humor.
Absorbed through the cornea where the prodrug is hydrolyzed to the active acid drug. Peak concentration in the aqueous humor is reached about 2 h after topical application.
Vd is about 0.16 L/kg.
Prodrug is hydrolyzed by esterases in the cornea to biologically active acid. The active drug reaching the systemic circulation is metabolized in the liver.
Systemic Cl is about 7 mL/min/kg. Metabolites are primarily excreted by the kidneys.
For reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.
1 drop (1.5 mcg) in affected eye(s) once daily in the evening.
Store unopened bottle in refrigerator (36° to 46°F). Once opened, bottle can be stored at room temperature up to 77°F for 6 wk. Keep container tightly closed and protected from light.
Precipitation occurs when eye drops containing thimerosal are mixed with latanoprost. If such drugs are used, administer with an interval of at least 5 min between applications.
None well documented.
Angina pectoris, chest pain (1% to 2%).
Rash/allergic skin reaction (1% to 2%); toxic epidermal necrolysis (postmarketing).
Blurred vision, burning, conjunctival hyperemia, foreign body sensation, increased pigmentation of the iris, itching, punctate epithelial keratopathy, stinging (5% to 15%); dry eye, excessive tearing, eye phobia, eye pain, lid crusting, lid edema, lid erythema, lid discomfort/pain, photophobia (1% to 4%); corneal edema and erosions, eyelash and vellus hair changes (including increased length, thickness, pigmentation, and number), eyelid skin darkening, herpes keratitis, intraocular inflammation (iritis/uveitis), keratitis, macular edema (including cystoid macular edema), misdirected eyelashes (postmarketing).
Upper respiratory tract infection, cold, flu (4%); asthma/exacerbation of asthma, dyspnea (postmarketing).
Muscle/joint/back pain (1% to 2%).
Category C .
Safety and efficacy not established.
Use caution in patients with active intraocular inflammation (eg, iritis, uveitis).
Changes to pigmented tissue (eg, iris, periorbital tissue [eyelid], eyelashes) may occur.
Macular edema, including cystoid macular edema, may occur.
Copyright © 2009 Wolters Kluwer Health.